Archives
-
RIPostC, Ketone Bodies, and Ferroptosis After Stroke
2026-09-19
A 2024 ACS Chemical Neuroscience study links remote ischemic postconditioning (RIPostC) with increased ketone-body production and reduced ferroptotic injury after experimental stroke. Its combination of rat middle cerebral artery occlusion and oxygen-glucose deprivation/reoxygenation models identifies preserved GPX4, reduced ACSL4 and iron burden, and improved energy metabolism as a mechanistic framework for neuroprotection.
-
Nullscript: HDAC Inhibitor Workflow Guide
2026-09-18
Nullscript is a histone deacetylase inhibitor with an unusually useful separation between HDAC enzyme inhibition and transcriptional facilitation. This guide shows how to deploy that profile in cardiac ischemia/reperfusion workflows, adapt necroptosis-focused assay logic from renal toxicology, and troubleshoot concentration, timing, and endpoint choices.
-
Recombinant Human FGF-19: Practical Workflow
2026-09-18
This guide provides a controlled workflow for using Recombinant Human FGF-19 in FGFR4 binding, cell proliferation, and metabolic regulation assays. It is intended for defined in vitro research and should not be treated as evidence of therapeutic efficacy, in vivo activity, or performance in cell systems lacking the relevant receptor context.
-
(-)-Epigallocatechin gallate (EGCG) in Neuroprotection
2026-09-17
Use (-)-Epigallocatechin gallate (EGCG) as a defined comparator in oxidative-stress, protein-aggregation, apoptosis, and neuronal survival workflows inspired by recent C. elegans research. This guide connects practical dosing and assay controls with the advantages and limitations of comparing a purified green tea catechin against complex fermentation extracts.
-
Bromodomain Inhibitor, (+)-JQ1: Applied Workflows
2026-09-17
Build more informative BET-response experiments with (+)-JQ1 by separating growth arrest from actual cell killing. This workflow connects BRD4-centered cancer assays with BRDT, inflammatory, and cytokine-response applications while emphasizing controls, timing, and storage practices.
-
LG 101506: A Practical RXR Modulator Workflow
2026-09-16
LG 101506 enables controlled pharmacological interrogation of RXR biology across reporter, transcriptional, and immune-cell assays. This workflow connects RXR signaling pathway research with the RBMS1–B4GALT1–PD-L1 axis while clearly separating established findings from testable hypotheses.
-
Bobcat339 for TET-Targeted DNA Methylation Studies
2026-09-16
Bobcat339 provides a practical chemical perturbation tool for testing how TET1/TET2 activity influences DNA methylation, enhancer states, and gene expression. This workflow connects biochemical inhibition with mesenchymal stem cell assays and the UHRF1–TGM2–autophagy findings reported in senile osteoporosis research.
-
KNUCKLES and Floral Meristem Termination
2026-09-15
The reference study shows that KNUCKLES coordinates floral meristem termination by connecting the WUS–CLV3 stem-cell circuit with auxin distribution and cytokinin activity. Its mechanistic evidence identifies PIN1 and IPT7 as chromatin-regulated targets, providing a framework for understanding how Arabidopsis establishes floral determinacy at the correct developmental stage.
-
CD44 Metabolic Rewiring in IDH-Mutant Leukemia
2026-09-15
The reference study identifies CD44 as a functional metabolic dependency in IDH-mutant leukemia, linking adhesion signaling to pentose phosphate pathway activity, NADPH generation, and sustained R-2HG production. Its isogenic CRISPR-based design supports a model in which combining mutant-IDH inhibition with CD44-directed intervention may address resistance more effectively than suppressing oncometabolite synthesis alone.
-
SGI-1027 DNA Methyltransferase Inhibitor Guide
2026-09-14
SGI-1027 combines DNMT-directed DNA methylation inhibition with a useful phenotypic readout: cancer-cell vacuolation and lysosomal membrane damage. This guide translates its biochemical profile into gene-reactivation assays, renal cancer combination studies, and practical troubleshooting workflows.
-
I-BET151 for BET Inhibition Workflows
2026-09-14
I-BET151 (GSK1210151A) provides a controllable way to test BET-dependent transcription in cancer models, from MLL-fusion leukemia research to emerging prostate cancer studies. This practical guide connects compound handling with apoptosis, cell cycle, chromatin, and disulfidptosis-oriented workflows while separating established findings from testable hypotheses.
-
Cyclodextrin Nano-Adsorbents for Uremic Toxins
2026-09-13
The reference study develops magnetic nanoparticles coated with α-, β-, or γ-cyclodextrin and examines how surface chemistry, incubation time, and solution composition affect uremic-toxin adsorption. Its central contribution is showing that adsorption can remain broadly independent of metabolite concentration within the tested conditions, highlighting the importance of host–guest interactions and matrix effects when designing retrievable blood-cleansing materials.
-
Epigenetic Silencing in Integrated Genetic Circuits
2026-09-12
The reference study shows that CRISPR-Cas9 integration can produce heterogeneous expression of multi-transcript genetic circuits through local epigenetic silencing rather than obvious sequence disruption. By combining fluorescence phenotyping, chromatin perturbation, and ATAC-seq, the authors connect circuit function with chromosomal accessibility and provide a framework for designing more reliable mammalian synthetic biology systems.
-
Tomivosertib Reduces Ectopic Activity in Human DRG
2026-09-11
The 2024 BRAIN study provides direct human evidence that acute MNK inhibition with tomivosertib suppresses spontaneous activity in cultured dorsal root ganglion neurons obtained from patients with radiculopathy. Rapid loss of eIF4E serine 209 phosphorylation and changes in action-potential properties support MNK signaling as a mechanistically relevant target for neuropathic pain research.
-
Toremifene in Breast Cancer: 20 Years of Evidence
2026-09-11
This review integrates two decades of clinical and pharmacologic evidence on toremifene, clarifying its role as a selective estrogen receptor modulator for selected postmenopausal patients with hormone-sensitive breast cancer. Its practical contribution is a balanced comparison with tamoxifen and aromatase inhibitors, emphasizing metabolism, tissue-selective effects, safety, and treatment selection.